Last edition
News about "IND Application "
Hemispherian Secures FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1
Hemispherian AS has received FDA clearance for its IND application to begin a Phase 1 trial of GLIX1, a first-in-class small molecule targeting DNA repair vulnerabilities in glioblastoma and other solid tumours.
IND Application | 05/08/2025 | By Mrinmoy Dey | 105
EuMentis Therapeutics Secures US FDA Clearance of IND Application for EM-221
EuMentis Therapeutics has received FDA clearance to initiate a Phase 2 clinical trial of EM-221, its novel PDE10A inhibitor, for the treatment of schizophrenia.
IND Application | 31/07/2025 | By Mrinmoy Dey | 105
Adcendo Receives FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
Tiffany-01 is an ongoing first-in-human Phase I multicenter, open-label, dose escalation study of ADCE-T02 as a monotherapy in patients with advanced solid tumors.
IND Application | 27/02/2025 | By Aishwarya | 339
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy